These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. HIV therapeutics: points from the recent literature. Laurence J AIDS Read; 2003 Jul; 13(7):305, 307. PubMed ID: 12889448 [No Abstract] [Full Text] [Related]
4. Interruption of antiretroviral therapy to augment immune control of chronic HIV-1 infection: risk without reward. Abbas UL; Mellors JW Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13377-8. PubMed ID: 12370421 [No Abstract] [Full Text] [Related]
5. When to start, when to STI (or, groping for the golden moment). Mascolini M IAPAC Mon; 2001 Apr; 7(4):114-7, 120-31. PubMed ID: 11700605 [No Abstract] [Full Text] [Related]
6. When to start antiretroviral therapy? NA-ACCORD stimulates the debate. Gallant JE AIDS Read; 2009 Feb; 19(2):49-50, 61. PubMed ID: 19271328 [No Abstract] [Full Text] [Related]
7. Baseline HIV RNA and the when to start question: time to stop asking this question? Mussini C AIDS; 2006 May; 20(8):1197-8. PubMed ID: 16691072 [No Abstract] [Full Text] [Related]
8. Beware of drug holidays before HIV salvage therapy. Hirschel B N Engl J Med; 2003 Aug; 349(9):827-8. PubMed ID: 12944566 [No Abstract] [Full Text] [Related]
9. Simply stated...on your mark, get set, go. Res Initiat Treat Action; 1998 Jul; 4(4):15. PubMed ID: 11365644 [TBL] [Abstract][Full Text] [Related]
11. Combination antiretroviral therapy for HIV infection. Maenza J; Flexner C Am Fam Physician; 1998 Jun; 57(11):2789-98. PubMed ID: 9636341 [TBL] [Abstract][Full Text] [Related]
12. Therapeutic strategies for HIV infection--time to think hard. Cooper DA; Emery S N Engl J Med; 1998 Oct; 339(18):1319-21. PubMed ID: 9791150 [No Abstract] [Full Text] [Related]
13. Initial plasma HIV-1 RNA levels and progression to AIDS in women and men. Sterling TR; Vlahov D; Astemborski J; Hoover DR; Margolick JB; Quinn TC N Engl J Med; 2001 Mar; 344(10):720-5. PubMed ID: 11236775 [TBL] [Abstract][Full Text] [Related]
14. [New biological monitoring of HIV infection]. Morand-Joubert L Rev Prat; 1998 Mar; 48(5):472-7. PubMed ID: 9781107 [No Abstract] [Full Text] [Related]
15. To start or not to start? Learned J Posit Aware; 2001; 12(5):28-9. PubMed ID: 11688482 [No Abstract] [Full Text] [Related]
17. Interleukin-2 in combination with zidovudine and didanosine is able to maintain high levels of CD4 cells and undetectable HIV viraemia. Simonelli C; Zanussi S; Comar M; Vaccher E; Giacca M; De Paoli P; Tirelli U AIDS; 1998 Jan; 12(1):112-3. PubMed ID: 9456263 [No Abstract] [Full Text] [Related]
18. A randomized controlled trial of a protease inhibitor (saquinavir) in combination with zidovudine in previously untreated patients with advanced HIV infection. Vella S; Lazzarin A; Carosi G; Sinicco A; Armignacco O; Angarano G; Andreoni M; Tambussi G; Chiodera A; Floridia M; Scaccabarozzi S; Facey K; Duncan I; Boudes P; Bragman K Antivir Ther; 1996 Aug; 1(3):129-40. PubMed ID: 11322246 [TBL] [Abstract][Full Text] [Related]
19. Understanding the guidelines for treating HIV disease. Chesebro MJ; Everett WD Am Fam Physician; 1998 Jan; 57(2):315-22, 328. PubMed ID: 9456994 [TBL] [Abstract][Full Text] [Related]
20. Optimal antiretroviral therapy: HIV-1 treatment strategies to avoid and overcome drug resistance. Grant PM; Zolopa AR Curr Opin Investig Drugs; 2010 Aug; 11(8):901-10. PubMed ID: 20721832 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]